Tau Peptide Immunogen Constructs for Tauopathy Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an unmet need for effective site-directed peptide immunogens and formulations to treat and prevent tauopathies, which are neurodegenerative diseases associated with abnormal Tau protein phosphorylation and aggregation.
Innovation Solution
Development of peptide immunogen constructs containing a B cell epitope from the Tau protein linked to a heterologous T helper cell epitope through an optional spacer, which stimulate the generation of highly specific antibodies to target Tau protein, used in immunotherapy for tauopathies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If peptide immunogen constructs are used to target Tau protein, then antibody specificity to Tau is improved, but the ability to effectively prevent and treat tauopathies remains unmet
Solution Approach 1:
The patent segments the Tau protein into specific epitopic regions (such as PHF-*tau* and other conformational epitopes) to create targeted peptide immunogen constructs. This segmentation allows the immune system to recognize and respond to specific pathological forms of Tau while maintaining high antibody specificity, thereby addressing both the precision and effectiveness requirements for tauopathy treatment
Solution Approach 2:
The patent modifies peptide constructs by incorporating specific amino acid sequences, post-translational modifications (such as phosphorylation at specific sites like Ser396), and conformational structures that mimic pathological Tau aggregates. These parameter changes enable the immunogens to elicit antibodies that recognize and bind to pathological Tau forms with high specificity and therapeutic effectiveness
2Manufacturing precision
If site-directed peptide immunogens are developed, then targeting precision to Tau aggregates is improved, but formulation complexity increases
Solution Approach 1:
The patent extracts specific epitopic sequences from the full-length Tau protein to create simplified peptide immunogen constructs. By taking out only the critical epitopic regions (such as the PHF-*tau* region and other conformational epitopes), the formulation achieves high targeting precision while reducing complexity compared to using full-length Tau protein or complex aggregate preparations
Solution Approach 2:
The patent creates simplified peptide copies that mimic the critical conformational and chemical features of pathological Tau aggregates. These peptide copies contain specific amino acid sequences and post-translational modifications that replicate the immunogenic epitopes of pathological Tau, enabling high targeting precision with simplified, more manageable formulations
Data Source
AI summary
The present disclosure is directed to individual peptide immunogen constructs targeting portions of the Tau protein for the treatment and/or prevention of tauopathies. The present disclosure is also directed to compositions containing the peptide immunogen constructs, methods of making and using the peptide immunogen constructs, and antibodies produced by the peptide immunogen constructs.